Literature DB >> 23667771

Interaction of insulin with prokinetic drugs in STZ-induced diabetic mice.

Mohamed A Fouad Shalaby1, Hekma A Abd El Latif, Mostafa E El Sayed.   

Abstract

AIM: To study the possible interactions of metoclopramide, domperidone and erythromycin in streptozotocin-induced diabetic mice treated with insulin by various parameters.
METHODS: Effects of the individual as well as combined drugs were studied in diabetic mice via estimation of the blood glucose and serum insulin levels, small intestinal transit (SIT), gastric emptying (GE), xylose absorption and glucose tolerance tests. Groups were given insulin 2 IU/kg s.c., metoclopramide 20 mg/kg p.o., domperidone 20 mg/kg p.o. and erythromycin 6 mg/kg p.o. individually and in combination. There were also normal and diabetic control groups. The first set of experiments was carried out to investigate the subchronic effect on blood glucose and serum insulin levels in diabetic mice of one week of daily dose administration of the tested drugs individually as well as the combination of insulin with each prokinetic drug. The other five sets of experiments were carried out to investigate the acute effect of a single dose of each drug individually and in combination on blood glucose and serum insulin levels, SIT, GE, oral xylose absorption and glucose tolerance tests.
RESULTS: The study included the prokinetic drugs metoclopramide (20 mg/kg), domperidone (20 mg/kg) and erythromycin (6 mg/kg), as well as insulin (2 IU/kg), which was individually effective in decreasing SIT, enhancing GE and increasing xylose absorption significantly in diabetic mice. Erythromycin tended to decrease blood glucose level and increase serum insulin level after 1 wk of daily administration in diabetic mice. Erythromycin potentiated the effect of insulin on blood glucose level and serum insulin level whereas other prokinetic agents failed to do so after repeated dose administration in diabetic mice. Metoclopramide or erythromycin in combination with insulin significantly decreased SIT, in diabetic mice, to lower levels than with insulin alone. Administration of prokinetic drugs along with insulin antagonized the action of insulin on xylose absorption. These combinations also increased the rate of glucose absorption from the gut.
CONCLUSION: The present study suggests that prokinetic drugs could potentially improve glycemic control in diabetic gastroparesis by allowing a more predictable absorption of nutrients, matched to the action of exogenous insulin. The use of prokinetics, such as erythromycin, may be interesting in the clinic in decreasing the need for insulin in diabetic patients. The dose of insulin may be safely decreased with erythromycin in chronic treatments.

Entities:  

Keywords:  Gastrointestinal motility; Insulin; Intestinal absorption; Prokinetic drugs; Streptozotocin

Year:  2013        PMID: 23667771      PMCID: PMC3644615          DOI: 10.4292/wjgpt.v4.i2.28

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  61 in total

1.  Gastrointestinal tract symptoms among persons with diabetes mellitus in the community.

Authors:  D Maleki; G R Locke; M Camilleri; A R Zinsmeister; B P Yawn; C Leibson; L J Melton
Journal:  Arch Intern Med       Date:  2000-10-09

2.  Metoclopramide in the treatment of diabetic gastroparesis.

Authors:  Allen Lee; Braden Kuo
Journal:  Expert Rev Endocrinol Metab       Date:  2010

3.  An inherent acceleratory effect of insulin on small intestinal transit and its pharmacological characterization in normal mice.

Authors:  Murali-Krishna-Reddy Peddyreddy; Steven Aibor Dkhar; Subramanian Ramaswamy; Amrithraj Theophilus Naveen; Deepak Gopal Shewade
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

4.  Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen.

Authors:  P Trinder
Journal:  J Clin Pathol       Date:  1969-03       Impact factor: 3.411

5.  Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes.

Authors:  Antonietta Russo; Julie E Stevens; Richard Chen; Diana Gentilcore; Richard Burnet; Michael Horowitz; Karen L Jones
Journal:  J Clin Endocrinol Metab       Date:  2005-05-17       Impact factor: 5.958

6.  Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus.

Authors:  E Schvarcz; M Palmér; J Aman; B Lindkvist; K W Beckman
Journal:  Diabet Med       Date:  1993 Aug-Sep       Impact factor: 4.359

7.  Altered glucose carrier expression: mechanism of intestinal adaptation during streptozocin-induced diabetes in rats.

Authors:  R N Fedorak; C I Cheeseman; A B Thomson; V M Porter
Journal:  Am J Physiol       Date:  1991-10

Review 8.  Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics.

Authors:  M Tonini; L Cipollina; E Poluzzi; F Crema; G R Corazza; F De Ponti
Journal:  Aliment Pharmacol Ther       Date:  2004-02-15       Impact factor: 8.171

Review 9.  [Gastrointestinal complications in diabetes mellitus].

Authors:  J Perusicová
Journal:  Vnitr Lek       Date:  2004-05

10.  Glucose absorption and gastric emptying in critical illness.

Authors:  Marianne J Chapman; Robert J L Fraser; Geoffrey Matthews; Antonietta Russo; Max Bellon; Laura K Besanko; Karen L Jones; Ross Butler; Barry Chatterton; Michael Horowitz
Journal:  Crit Care       Date:  2009-08-27       Impact factor: 9.097

View more
  2 in total

1.  Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling.

Authors:  Zi-Yu Zhou; Li-Wei Ren; Ping Zhan; Han-Yan Yang; Dan-Dan Chai; Zhi-Wen Yu
Journal:  Acta Pharmacol Sin       Date:  2016-05-16       Impact factor: 6.150

2.  Antibacterial and laxative activities of strictinin isolated from Pu'er tea (Camellia sinensis).

Authors:  Sheng-Kuo Hsieh; Jun-Rui Xu; Nan-Hei Lin; Yue-Chiun Li; Guan-Heng Chen; Ping-Chung Kuo; Wen-Ying Chen; Jason T C Tzen
Journal:  J Food Drug Anal       Date:  2016-06-21       Impact factor: 6.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.